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Abstract
Hepatocyte nuclear factor 4 alpha (HNF4α) nuclear receptor is a master regulator of hepa-
tocyte development, nutrient transport and metabolism. HNF4α is regulated both at the
transcriptional and post-transcriptional levels by different mechanisms. Several kinases
(PKA, PKC, AMPK) were shown to phosphorylate and decrease the activity of HNF4α. Acti-
vation of the ERK1/2 signalling pathway, inducing proliferation and survival, inhibits the
expression of HNF4α. However, based on our previous results we hypothesized that
HNF4α is also regulated at the post-transcriptional level by ERK1/2. Here we show that
ERK1/2 is capable of directly phosphorylating HNF4α in vitro at several phosphorylation
sites including residues previously shown to be targeted by other kinases, as well. Further-
more, we also demonstrate that phosphorylation of HNF4α leads to a reduced trans-activa-
tional capacity of the nuclear receptor in luciferase reporter gene assay. We confirm the
functional relevance of these findings by demonstrating with ChIP-qPCR experiments that
30-minute activation of ERK1/2 leads to reduced chromatin binding of HNF4α. Accordingly,
we have observed decreasing but not disappearing binding of HNF4α to the target genes.
In addition, 24-hour activation of the pathway further decreased HNF4α chromatin binding
to specific loci in ChIP-qPCR experiments, which confirms the previous reports on the
decreased expression of the HNF4a gene due to ERK1/2 activation. Our data suggest that
the ERK1/2 pathway plays an important role in the regulation of HNF4α-dependent hepatic
gene expression.
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Introduction
Hepatocyte nuclear factor 4α (HNF4α) is a protein that was first identified as an activator of
the Transthyretin gene expressed upon binding to a cis-regulatory element [1]. The transcrip-
tion factor (TF) was then purified [2], and the analysis of the gene showed that it is a member
of the nuclear receptor superfamily. Later studies demonstrated its fundamental role in several
processes [3]. Accordingly, the HNF4α knockout mouse model is embryonic lethal since the
TF is required for gastrulation and liver development [4].
In adults, HNF4α is expressed in the liver, pancreas, intestines and the kidney [5]. It par-
ticipates in the regulation of a multitude of genes, in addition, it is considered as a master
regulator in hepatocytes [6]. Genes of lipid and glucose metabolism [7], transporters and tran-
scription factors are among the most important targets of the HNF4α protein [8, 9]. Although
it reacts to environmental stresses, such as fasting or feeding, it has long been considered as an
orphan receptor [10].
Crystallization studies have shown, however, that it can be co-crystallized as a homodimer
with long-chain fatty acids in its ligand-binding pocket [11]. Furthermore, the ligand seemed
to be a constitutive activator, suggesting that HNF4α is constitutively active [12]. Since several
functional studies have demonstrated that the transcription factor is not constitutively activat-
ing its target genes, the investigation of post-translational modifications and the search for
interacting partners has begun [13, 14]. These latter experiments revealed the interaction of
HNF4α with different transcription factors (e.g. farnesoid X receptor FXR) [15], co-activators
and co-repressors [15, 16].
The study of potential post-translational modifications has identified several acetylation,
ubiquitilation and phosphorylation sites. Mass spectrometry analyses of post-translational
modifications by phosphopeptide mapping showed that HNF4α can be phosphorylated in the
hepatoma-derived HepG2 cell line at several sites [13]. Different kinase cascades were also
shown to phosphorylate the protein at specific residues. Protein kinase C (PKC) has the most
important inhibitory effect by phosphorylating serine 78 [17]. Protein kinase A (PKA) [18]
and p38 [19] were also shown to phosphorylate the protein. However, these latter results seem
to be controversial. Finally, AMP activated kinase (AMPK) targets serine 313 [20] and the
phosphorylation of this amino acid residue was also shown to decrease the activity of the tran-
scription factor, however, to a lesser extent than PKC [17].
ABCC6 is a gene of the ATP-binding cassette (ABC) transporter family. It encodes a protein
mainly expressed in the basolateral membrane of hepatocytes, which transports an unknown
substrate from the cells to the bloodstream. Loss-of-function recessive mutations of the gene
lead to the development of ectopic soft tissue calcification and the fragmentation of elastic
fibres. The resulting syndrome is called Pseudoxanthoma elasticum (PXE), characterized by
dermatologic, ocular and cardiovascular symptoms (reviewed in [21]).
We have identified several cis-regulatory elements at the gene promoter and a primate-
specific sequence in the first intron of the gene [22]. We have also shown that a transcription
factor network including HNF4α, CCAAT/enhancer binding protein (CeBP) α and β bind
these cis-regulatory elements [23]. Our results clearly suggested that HNF4α orchestrates
this network and it is responsible for the tissue- and cell-type specific expression of ABCC6
[22, 24].
While investigating the transcriptional regulation of the human ABCC6 gene in human cell
lines, we observed that the activation of several kinase cascades (PKC, AMPK and ERK1/2)
inhibits the expression of the gene via HNF4α [24]. In our model system, HNF4α was intro-
duced in a eukaryotic expression plasmid and the gene expression was not sensitive to ERK1/
2. Therefore, in the present study we investigated whether HNF4α is a direct target of ERK1/2
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phosphorylation. Here we show that ERK1/2 directly phosphorylates HNF4α, which decreases
the trans-activating capacity of the transcription factor.
Results
We have shown that the expression of ABCC6 is inhibited by ERK1/2 kinase via HNF4α [24].
It has also been reported that ERK1/2 can decrease HNF4α expression [25]. However, in our
experimental system we did not investigate the effect of ERK1/2 on the endogenous HNF4a
gene, but we rather used a plasmid-based eukaryotic expression system, which was not sensi-
tive to ERK1/2. Thus, we hypothesized that ERK1/2 directly inhibits the HNF4α protein.
HNF4α is phosphorylated by ERK1/2
In order to confirm this hypothesis, we carried out in vitro phosphorylation assay on HNF4α
by ERK1. We used in vitro translated human recombinant HNF4α protein—not decorated
with any post-translational modifications–in fusion with GST-tag at N-terminal, ERK1 kinase
and radioactively labelled [γ-32P] ATP. The samples were run on SDS-PAGE and subjected to
autoradiography. As shown on Fig 1, ERK1 kinase is capable of autophosphorylation, [26], but
it also phosphorylated HNF4α, as indicated by a band in the middle lane.
Phosphopeptide mapping of detected phosphorylation sites
Subsequently, we asked which serine/threonine residue(s) are phosphorylated. For this, the
above described phosphorylation assay was performed in duplicates, where one of the samples
was labelled only with non-radioactive phosphate. This ERK1-phosphorylated HNF4α sample
was cut out from the gel and subjected to mass spectrometry analysis. We have identified a
great number of phosphorylated amino acid residues, although, if two sites were adjacent, the
method we used could not distinguish between them (Fig 2 and Table 1). Affected phosphory-
lation sites appear in the DNA binding domain, the hinge, the ligand-binding domain and the
C-terminus of HNF4α, as well. In spite of the numerous positions identified, interestingly, the
previously reported main phosphorylation site, the S87 residue of the human protein (corre-
sponding to rat S78) has not been found in our experiment (see Discussion) [17]. We have
concluded that ERK1/2 is capable of phosphorylating human HNF4α at multiple sites, which
occur at previously described (S138/T139, S142/S143, S147/S148, S151, T166/S167, S313) and
new positions reported here first (S95, S262/S265, S451, T457/T459). Moreover, our results
show that the ERK1-targeted positions overlap with the phosphorylation sites of other kinases,
for instance PKA, p38 and AMPK (see Introduction and Discussion).
HNF4α phosphorylation via ERK1/2 inhibits ABCC6 transcriptional activity
This great number of amino acid residues targeted by ERK1 phosphorylation raised the ques-
tion of the functional relevance of the observed phenomenon. In order to answer this question,
several phosphorylation sites were selected and investigated in luciferase reporter gene assay.
Five phosphorylation sites were chosen for further examination. Some of them were already
studied previously, while we also investigated residues detected for the first time in the previ-
ous experiment. Mutations were designed for the following serine or threonine phosphoryla-
tion sites creating phosphomimetic (glutamate or aspartate) or neutral (alanine) mutants:
S87D, T166A/S167D, S313D, S451E, T457A/T459E and S451E/T457A/T459E triple mutant. If
two phosphorylation sites were adjacent or in very close proximity, both were mutated.
Serine 87 mutation to aspartate was chosen because this site is undoubtedly a target for
PKC phosphorylation, which abolishes HNF4α activity [17]. Thus, this site served as a positive
HNF4α phosphorylation by ERK1/2
PLOS ONE | DOI:10.1371/journal.pone.0172020 February 14, 2017 3 / 19
control in our experiments. T166/S167 is a site, which was described to be phosphorylated by
p38α or p38β MAP kinases [13, 19], therefore also suggesting an important role of these two
adjacent sites. The logic in our mutational screen was similar to that observed in the literature,
i.e. to change only one site into a phosphomimetic mutation and mutate the other to a neutral
one, if there were two adjacent phosphorylation sites. Accordingly, T166 was mutated into a
neutral amino acid (alanine), whereas S167 became a phosphomimetic mutant (aspartate).
The site S313D is the target of phosphorylation by AMPK [14]. Finally, we newly identified
the sites S451 and T457/T459. Therefore, we designed a neutral/phosphomimetic double
mutant, in this case the phosphomimetic mutant being glutamate. Lastly, S451/T457/T459
were mutated in order to see the effect of a triple mutant, by including the former S451E
mutant. Thus, we intended to examine if these C-terminal amino acids take part in transcrip-
tional regulation when phosphorylated.
Fig 1. In vitro phosphorylation assay of HNF4α by ERK1 kinase. The phosphorylation assay was carried out with in vitro
translated human recombinant HNF4α protein, ERK1 kinase and radioactively labelled [γ-32P] ATP. HNF4α does not contain any
post-translational modifications, but it has a GST-tag at N-terminal. The samples were run on SDS-PAGE and subjected to
autoradiography. ERK1 kinase is capable of autophosphorylation.
doi:10.1371/journal.pone.0172020.g001
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After creating all the mutants, co-transfection was performed with a luciferase reporter
gene under the control of ABCC6 promoter and different HNF4α mutants into HeLa cells
lacking endogenous HNF4α expression. The obtained results were normalized first for the
background noise, then for transfection efficiency by the co-transfected control reporter vec-
tor, which essentially represents transfection efficiency. As shown on Fig 3, wild type HNF4α
results in similar activity to T166A/S167D, S451E and T457A/T459E, and S451E/T457A/
T459E (data not shown), therefore, we regard these residues as not being responsible for
implementing the effect of phosphorylation on transcriptional activity or gene expression in
this assay. However, both S87D (used as positive control) and S313D have significant inhibi-
tory effect on ABCC6 promoter activity: they decrease the activity to approximately 15% and
55%, respectively, compared to control. In conclusion, the phosphorylation site S313 targeted
by both ERK1 and AMPK is responsible to have an inhibitory effect on transcription.
HNF4α and H3K27ac histone mark overlap in ChIP-Seq
In order to further confirm the functional relevance of HNF4α phosphorylation by ERK1/2,
we carried out a cell-based assay, which reflects appropriately the endogenous intracellular
processes. First, we screened control HepG2 cells for active HNF4α binding sites prior to
selecting some genomic target loci to investigate the effect of ERK1/2 on HNF4α binding.
To detect active HNF4α binding sites in the HepG2 cells at the genome-wide level, we car-
ried out chromatin immunoprecipitation followed by sequencing (ChIP-seq) with an antibody
Fig 2. Phosphorylated sites on HNF4α protein by ERK1 kinase detected by mass spectrometry. Non-radioactively phosphorylated
HNF4α by ERK1/2 was cut out from the polyacrilamid gel. Tryptic peptide fragments were analysed by mass spectrometry. Affected
phosphorylation sites (indicated by lollipops) appear in the DNA binding domain (DBD), the hinge, the ligand-binding domain (LBD) and
the C-terminus of HNF4α, as well. The phosphorylated amino acid residues can be attributed to either previously described sites (S138/
T139, S142/S143, S147/S148, S151, T166/S167, S313) or new positions reported first here (S95, S262/S265, S451, T457/T459).
doi:10.1371/journal.pone.0172020.g002
Table 1. Phosphorylated amino acid residues identified by mass spectrometry. In vitro phosphorylated HNF4αwas subjected to mass spectrometry
analysis. The fragments containing the phosphorylated amino acid residues correspond to phosphorylation sites on the HNF4α protein. Detected phosphory-
lation sites (serine/threonine residues) in the cryptic fragments are marked bold and underlined. Affected phosphorylation sites appear in the DNA binding
domain (DBD), the hinge, the ligand-binding domain (LBD) and the C-terminus of HNF4α, as well.
Sequence Identified phosphorylation sites Part of HNF4α
KNHMYSCR S95 DBD
QNERDRISTRRSSYED S138/T139 hinge
QNERDRISTRRSSYED S142/S143 hinge
STRRSSYEDSSLPSINALLQ S147/S148 hinge
STRRSSYEDSSLPSIN S151 hinge
EVLSRQITSPVSGIN T166/S167 LBD
HCPELAEMSRVSIR S262, S265 LBD
GKIKRLRSQVQVSLED S313 C-terminus
SAIPQPTITKQE S451, T457, T549 C-terminus
doi:10.1371/journal.pone.0172020.t001
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against HNF4α and—in a parallel experiment on chromatin prepared from the same HepG2
sample—with an antibody against acetylated histone 3 lysine 27 (H3K27ac). The H3K27ac
covalent modification of the chromatin indicates active regulatory regions, which are often
enhancers.
From the ChIP-seq sample immunoprecipitated with HNF4α antibody, 8,748 transcription
factor binding sites (TFBSs) could be identified (S1 Table). We have plotted these sites on a
read distribution plot and we have sorted them based on tag density. Then we have matched
the signal of the active histone mark H3K27ac (Fig 4A). Fig 4B illustrates on a Venn diagram
that over 75% of HNF4α peaks overlap with H3K27ac peaks.
Fig 3. Luciferase assay measuring ABCC6 promoter activity of HNF4α phosphomimetic mutants in HeLa cells. Mutations were designed for
serine or threonine phosphorylation sites creating phosphomimetic (glutamate or aspartate) or neutral (alanine) mutants. For luciferase assays, triple co-
transfection was performed with the phACCC6(-332/+72)Luc construct composed of the ABCC6 promoter fragment, pcDNA5-FRT/TO plasmid encoding
HNF4α variants and pRL-TK Renilla luciferase Control Reporter Vector. Luciferase activity was measured 48 hours after transfection. Relative luciferase
activity was calculated by normalizing for background noise and for transfection efficiency by the co-transfected control reporter vector. The error bars
represent S.D. Tukey-HSD test was performed. Significance versus WT HNF4 alpha is indicated by asterisks: *p<0.05; **p<0.01.
doi:10.1371/journal.pone.0172020.g003
HNF4α phosphorylation by ERK1/2
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We have also plotted the average tag density of the HNF4α peaks and the H3K27ac signals,
indicating that the HNF4α TFBSs represent a Gaussian distribution, whereas histone signals
show the peak-valley-peak shape (Fig 4C). We have also observed that 451 peaks overlap with
the TSS (+1 is part of the binding site) and in these cases, the average tag density of H3K27ac is
Fig 4. (A) Read distribution plot of HNF4α and H3K27ac upon vehicle treatment, relative to the 8,748 HNF4α peaks in 2-kb frames. Peaks are
sorted according to HNF4α tag density. (B) Area-proportional Venn diagram illustrating the overlap between H3K27ac regions and HNF4α peaks.
(C) Histogram shows the average tag density of vehicle-treated HNF4α peaks and H3K27ac signals at the sites of 8,748 HNF4α binding sites. (D)
Motif enrichment of 8,748 HNF4α peaks. The P value and target and background (Bg) percentages are included for each motif. (E) IGV snapshot
of HNF4α and H3K27ac ChIP-seq coverage representing eight selected genomic regions upon vehicle treatment. HBB promoter: negative control
region. The interval scale is 50 in both cases. Peaks, highlighted with grey lines, represent the sites of the investigated HNF4α-target genomic
regions.
doi:10.1371/journal.pone.0172020.g004
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twice as high as in the case of the distribution centered to HNF4 alpha peaks (Fig 4C and S1
Fig). Furthermore, 33% and 71% of the HNF4 alpha peaks are within +/- 5 kb and +/- 30 kb
from the TSS, respectively. These results indicate that the predicted TFBSs follow the expected
typical patterns and confirm that these are real TFBSs without significant non-specific binding.
To further validate the predicted TFBSs, we applied motif enrichment analysis on these
regions. As expected, the consensus motif of HNF4α (61.33%) and its cooperative factors, such
as forkhead box A1 (FoxA1) and C/EBPα, are enriched. Motif of the activator protein 1 (AP-
1), HNF1 homeobox A (HNF1α) and GATA binding protein 4 (GATA4) were also identified
(Fig 4D). By annotating the 8,748 HNF4α TFBSs, many of them are located near genes related
to PPAR and insulin signalling or fatty acid metabolism. Furthermore, when we verified the
pathways enriched for genes with HNF4α binding sites, the membrane transport-related
ABC-transporter genes also appeared (Table 2). Therefore, we selected the following target
genes for further experiments: 4-hydroxyphenylpyruvate dioxygenase (HPD), Pyruvate kinase,
liver and red blood cell (PKLR). We have also selected the ABCC6 gene since we and others
have reported that HNF4α binds the promoter of this gene [24, 27]. Apolipoprotein A1
(APOA1) is a well-known target for HNF4α, therefore we also included it in the investigation.
Indeed, our ChIP-seq results also showed that it is bound by HNF4α together with the pres-
ence of the H3K27ac, suggesting that they have active regulatory regions in HepG2 cells. More-
over, it is listed as a gene having a role in PPAR signalling in the KEGG pathways obtained
from our ChIP-seq data. Finally, we have identified Biliverdin A (BLVRA) and Biliverdin B
(BLVRB), which are closely connected to heme oxygenase in heme catabolism, a known target
of HNF4α, which plays a role in anti-oxidative and anti-inflammatory defence mechanisms.
We have also selected a negative control region: the β-globin promoter, which was devoid of
acetylation and HNF4α binding (Fig 4E).
ERK1/2 activation leads to reduced binding of HNF4α to specific
genomic regions
In the following experiment we used the selected genomic target regions to investigate the
dynamics of HNF4α binding to our genes of interest upon ERK1/2 induction in HepG2 cells.
Table 2. Top 15 biological pathways related to the 8,748 HNF4α binding sites. Data derived from KEGG
database.
Top 15 pathway terms log P-value
Peroxisome -11.59335105
Adherens junction -10.88593944
Focal adhesion -9.508833554
PPAR signaling pathway -9.255948133
Leukocyte transendothelial migration -9.21522799
Insulin signaling pathway -9.164553569
Adipocytokine signaling pathway -9.018794995
Glycine, serine and threonine metabolism -8.616929048
Complement and coagulation cascades -8.079259745
Axon guidance -7.860829255
Primary bile acid biosynthesis -7.152608222
Tight junction -6.376981421
ErbB signaling pathway -6.124131582
ABC transporters -5.556926349
Fatty acid metabolism -5.556926349
doi:10.1371/journal.pone.0172020.t002
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Since phosphorylation of proteins is a fast process, and happens within minutes [28], we
decided to perform short-term (30 minutes) treatment of HepG2 cells with epidermal growth
factor (EGF), which activates the ERK1/2 signalling cascade after binding to its receptor.
In our ChIP-qPCR experiments, enrichments of immunoprecipitated target fragments by
anti-HNF4α antibody were compared to the input fraction or to the selected negative control
region (β-globin) for TF occupancy, where no binding of the protein of interest is expected.
Similarly, we systematically performed another negative control, immunoprecipitation with
IgG, used as non-specific antibody. We carried out 7 independent experiments under the
same conditions in HepG2 cells and as hypothesized, 30 minutes treatment led to reduced
HNF4α binding to the selected target sites, as shown on Fig 5 and S2 Fig. We evaluated the
effect of short-term EGF treatment by performing a one-sample t-test after normalization of the
immunoprecipitated fraction from the treated cells for each target gene to their respective con-
trols. Accordingly, highly significant effect was observed after short treatment (p<0.004). More
precisely, after 30 minutes treatment, based on our ChIP-qPCR data, there is a substantial loss
Fig 5. ChIP-qPCR results showing HNF4α occupancy on seven genomic regions of hepatic HNF4α target genes. Immunoprecipitation of
chromatin from HepG2 cells was performed with anti-HNF4α or IgG antibody untreated or treated with EGF for 30 mins. Enrichment was compared to %
input (y axis). HNF4α binding (black columns) is decreased after short EGF treatment (grey). BLVR A: Biliverdin A, BLVR B: Biliverdin B, HPD:
4-hydroxyphenylpyruvate dioxygenase, PKLR: Pyruvate kinase, liver and RBC, ABCC6: ATP-binding cassette subfamily C, member 6 and APOA1:
Apolipoprotein A1. Beta globin: negative control region. Beads represent immunoprecipitation performed without any antibody. S.D. is indicated on the
figure. Results of a representative experiment (n = 7) are shown.
doi:10.1371/journal.pone.0172020.g005
HNF4α phosphorylation by ERK1/2
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of HNF4α binding compared to the control case for the individual target genes, shown on S2
Table. This effect was further enhanced by 24h EGF treatment. Collectively, our data suggest
that ERK1/2 phosphorylates HNF4α both in vitro and in vivo, leading to the reduced DNA
binding capacity of the transcription factor at target loci.
Discussion
We have shown previously that HNF4α regulates ABCC6 gene expression. We have also dem-
onstrated that ERK1/2 activation inhibits HNF4α-dependent ABCC6 expression. We hypothe-
sized that HNF4α is phosphorylated by ERK1/2 leading to its reduced trans-activational
capacity in addition to the reduced expression of the HNF4a gene. Here we have demonstrated
that ERK1 is able to phosphorylate HNF4α at several serine and threonine residues. We have
also shown that phosphorylation of HNF4α inhibits its trans-activational capacity in reporter
gene assay and its chromatin binding activity as determined by ChIP-qPCR confirming the
physiological relevance of our findings.
HNF4α plays a major role in hepatic development and it is a master gene regulator in dif-
ferentiated hepatocytes. It regulates thousands of genes playing important roles in glucose,
lipid and amino acid metabolism, bile acid synthesis, detoxification and inflammation. Our
results are in harmony with these findings. In our ChIP-seq experiments, in non-treated
HepG2 cells we found almost 9000 genomic HNF4α binding sites associated with 5500 genes.
More than 60% of them are canonical HNF4α elements, but binding motifs for FoxA1,
C/EBPα and HNF1α were also enriched in the immunoprecipitated DNA fraction. These
sequences are known to be bound by TFs interacting with HNF4α, thereby strengthening the
validity of our findings. CEBPα has been previously reported as being part of a complex with
HNF4α forming together an intricate regulatory network of hepatocyte gene expression [22,
29]. HNF1α is a transcription factor known to interact with HNF4α, where HNF4α enhances
HNF1α-mediated activation of hepatic transcription [30]. Our data also indicated that we
identified actively transcribed HNF4α-regulated genes since those sites were also occupied by
the H3K27ac histone mark, a hallmark of active genes [31] (Fig 4B). Finally, we were able to
identify typical HNF4α target genes in the immunoprecipitated fraction. Furthermore, the
KEGG pathway analysis of all identified HNF4α target genes revealed similar cascades to those
available as literature data. Among the typical genes ABCC6,ABCA1,ALDOB (aldolase B),
APOA1, APOB, APOCIII,BLVRA and B, CYP7A1,HNF1a and 4a, HPD, PKLR and SLC2A2
(GLUT2) were observed.
From these target genes we selected six—BLVRA, BLVRB, HPD, ABCC6, PKLR and APOA1
—for our further experiments. The latter two genes are part of the 451, which have an HNF4α
binding site overlapping with the TSS (S1 Fig). Pyruvate kinase (PKLR) plays an important
role in regulating glucose metabolism [7]. The other genes we have selected are also implicated
in metabolism. 4-Hydroxyphenyl pyruvate dioxygenase (HPD) is an enzyme participating in
tyrosine metabolism [32]. Mutations of the gene lead to a benign Mendelian disorder called
Tyrosinaemia (type III). Apolipoprotein A1 (APOA1) plays primary role in lipid transport
[33]. The biliverdin reductase genes catalyze the synthesis of bilirubin from biliverdin and thus
participate in heme metabolism and the antioxidant pathway. Although the molecular func-
tion of ABCC6 is still unclear, it is protective against ectopic calcification, moreover, it might
play a role in ATP homeostasis and in ROS elimination [23, 24, 34].
Our ChIP-qPCR experiments confirmed our initial hypothesis suggesting that ERK1/2 has
both post-translational and probably transcriptional effects on HNF4α. These experiments
showed that already short activation of the ERK1/2 pathway decreased the DNA binding
capacity of HNF4α in living cells suggesting a post-translational effect. This rapid decrease
HNF4α phosphorylation by ERK1/2
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became even more pronounced after 24h ERK1/2 activation suggesting the inhibition of
HNF4a gene expression, as described earlier [29]. We chose the ChIP-qPCR method to detect
the binding capacity alterations of the TF to a limited number of genomic loci to allow us reli-
able quantification of the changes. By using this approach, we could also perform several inde-
pendent experiments, which was essential since the variability of ChIP experiment results is
generally high.
Our experiments also proved that the rapid post-translational effect of ERK1/2 activation
on HNF4α is mediated by the phosphorylation of the protein. We have shown that an in vitro
translated HNF4α protein is phosphorylated at multiple sites by the activated ERK1. Several
studies have revealed that HNF4α can be phosphorylated by several kinases, for instance, PKC,
PKA, AMPK and p38. Phosphorylation can alter its DNA-binding affinity, intracellular locali-
zation and trans-activation capacity [35]. Phosphorylation of the highly conserved S87 by PKC
drastically decreases the DNA binding capacity and stability of the protein [17]. Similarly, the
cAMP-activated PKA phosphorylates HNF4α at the S142/S143 position [18]. This leads to
reduced DNA binding activity of the TF, however, the reduced trans-activational potential
could not be confirmed in luciferase reporter gene assay setup [18]. More recently, it has been
shown that Thyroid-stimulating hormone (TSH) induces PKA, which leads to decreased
nuclear localization of HNF4α in HepG2 cells [36]. AMPK has been defined as a metabolic
master switch [8]. It phosphorylates the conserved S313 residue of HNF4α leading to the inhi-
bition of the dimerization of the TF [20] and thereby its trans-activational capacity. AMPK
activation dramatically decreases the transcription of various HNF4α target genes in hepato-
cytes. Finally, the role of p38 seems to be controversial. Some papers indicate that phosphory-
lation of HNF4α at residue T166/S167 by this kinase increases trans-activational potential of
the TF [19, 37]. Others show indirect effect [20, 38], while some suggest an inhibitory role for
p38 [9].
We have also investigated the functional relevance of the different residues shown to be
phosphorylated by ERK1. In these experiments we used the luciferase reporter gene cloned
downstream of the ABCC6 promoter, a construct used in our previous studies [22, 24]. We
have shown that this promoter is induced by HNF4α. In our present experiments we co-
expressed this reporter gene with wild-type (wt) or different phosphomimetic HNF4α
mutants.
The positive control mutant mimicking PKC phosphorylation resulted in significantly
reduced reporter gene activity relative to the wt, as described earlier [17]. We have also ana-
lyzed the sites firstly identified in the present study (S451, T457/T459) and the sites corre-
sponding to the previously described potential p38 site (T166/S167) [19]. In contrast to the
previous studies, the phosphomimetic mutants of this site did not affect the trans-activational
potential of HNF4α. In these experiments, only the site previously shown as targeted by
AMPK (S313) showed diminished reporter gene activity [20, 38]. Collectively, our results
clearly demonstrate that ERK1/2 activation results in HNF4α phosphorylation and reduced
DNA binding capacity.
The ERK1/2 pathway is activated under several physiologic and pathologic conditions
underlying the importance of our findings. For example, bile salts function as signalling mole-
cules through the Sphingosine-1-phosphate receptor 2 (S1PR2) G protein coupled receptors
(GPCRs), which activate ERK1/2 to control hepatic glucose, lipid and drug metabolism ([39–
41]; [42] and references therein). The resulting rapid downregulation of HNF4α activity
reduces the expression of the gluconeogenic genes PEPCK and G-6-Pase [40], or the gene
encoding the major enzyme in bile acid synthesis, CYP7A1 [43].
In addition to the GPCR pathway, bile acids also activate specific nuclear receptors (e.g.
FXR and vitamin D receptor (VDR)). While VDR is able to directly activate ERK1/2 [44], FXR
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is the major bile acid-responsive ligand-activated transcription factor and it is responsible for
bile acid homeostasis [45, 46]. FXR induces the expression of SHP (small heterodimer part-
ner), an orphan nuclear receptor without DNA binding domain. SHP binds HNF4α and
inhibits its binding to the target cis-regulatory elements (e.g. the bile acid response element
(BARE) of the Cholesterol 7α hydroxylase (CYP7A1) gene promoter) [47]. SHP is also activated
by ERK1/2 leading to an intricate network of HNF4α inhibition both in the short and longer
term [42, 46, 48].
Finally, the ERK1/2 pathway is also activated by other mechanisms including oxidative
stress (ROS) [49], growth hormones (such as HGF, EGF and FGF15/19 [24, 50]) and cytokines
(IL1 and TNFα [9, 14, 19]), as well. These factors also lead to the reduced activity of HNF4α
and thereby the downregulation of several genes. According to our results, the mechanism of
the short-term inhibition of HNF4α is its phosphorylation, suggesting that ERK1/2 plays a piv-
otal role in the coordinated regulation of a great number of hepatic genes via the rapid post-
translational modification of HNF4α.
Materials and methods
Cell culture
HepG2 human hepatoma cell line was obtained from ATCC (ATCC HB-8065) and cultured in
Advanced MEM (ThermoFisher) supplemented with 10% FBS, 2mM L-glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin. HeLa cells were obtained from ATCC and cultured
according to the manufacturer’s instructions (DMEM supplemented with 10% FBS, 2mM L-
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin). For EGF treatment, cells were
changed to serum free medium 24h before the addition of the chemical, and then treated for
30 minutes or 24 hours with human recombinant epidermal growth factor (Sigma–Aldrich) at
100 ng/ml final concentration.
In vitro phosphorylation assay
The reaction was performed in a mixture (30 μl final volume) containing kinase buffer [28],
500 ng ERK1 kinase (Sigma ERK1 kinase datasheet, cat number: E7407) HNF4α human
recombinant protein with GST-tag at N-terminal (Abnova HNF4 alpha datasheet, cat number:
H00003172-P01) and 20 uM ATP including 1 μCi [γ-32P] ATP. The reaction was initiated by
the addition of ATP. After incubation at 30˚C for 30 min, the reaction was stopped by adding
10 μl of 4X concentrated SDS sample buffer. Samples were subjected to SDS-PAGE using 10%
running gels. After drying, gels were subjected to autoradiography for 2–12 hours.
Phosphopetide mapping of HNF4α
The gel band containing HNF4α protein was processed, reductively alkylated with DTT and
iodoacetamide and then digested with trypsin in 20 mM ammonium bicarbonate buffer. An
aliquot was then run a Thermo/Dionex Ultimate RSLC nano system using a 75um x 15 cm C
18 PepMap column (Thermo/Dionex) coupled to a Thermo LTQ Orbitrap Velos Pro. We
used a TOP 15 MS method (65 min linear gradient from 5–40% B (80% acetonitrile in 0.1%
formic acid) with multi-stage activation (to detect neutral loss of phosphate from phosphopep-
tides). The obtained data file was analysed by the Mascot search engine against the sequence
provided (HNF4α with N-terminal GST-tag). The phosphopeptide assignment was done on
peptides above a mascot ion score of 20 which may include the same peptide a number of
times as the system has detected that peptide on more than one occasion. The indication is
that the higher the ion score for the peptide the more likely that the assignment is correct.
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HNF4αmutations
Wild-type plasmid containing the full human HNF4α gene and pcDNA5-FRT/TO expression
backbone was purchased from Addgene. Amino acid numbering in this article refer to muta-
tions of the human HNF4α gene, whereas mutations of the rat HNF4α gene are adjusted to the
human numbering. Mutations were designed for the following serine or threonine phosphory-
lation sites creating phosphomimetic (glutamate or aspartate) or neutral (alanine) mutants:
S87D, T166A/S167D, S313D, S451E, T451A/T459E. If two phosphorylation sites were adjacent
or in very close proximity, both were mutated. Gene synthesis and site-directed mutagenesis
were performed by the biotechnology company GenScript. The gene was re-cloned from
pcDNA3+ into pcDNA5-FRT/TO plasmid.
Transfection and luciferase experiments
HeLa cells were plated onto 96-well plates starting with 10.000 cells/well. FuGENE HD trans-
fection reagent (Promega) complex containing serum-free medium and 2 μg total plasmid
DNA was added to cells in growth medium. Triple co-transfection was performed with the
phACCC6(-332/+72)Luc construct ((see [24]) composed of the ABCC6 promoter fragment
(-332/+72) cloned upstream of the luciferase coding cassette in the pGL3-Basic vector (Pro-
mega)), pcDNA5-FRT/TO plasmid encoding HNF4α variants (GenScript) and pRL-TK
Renilla luciferase Control Reporter Vector (Promega). Cells were harvested and lysed after 48
hours. Luciferase activity was determined by Victor luminometric plate reader (Perkin Elmer)
using the DualGlo Luciferase system (Roche). The obtained results were normalized firstly for
the background noise, then for transfection efficiency by the co-transfected control reporter
vector.
ChIP (chromatin immunoprecipitation) assay
Formaldehyde was added directly to the culture media of flasks containing 10x106 HepG2
cells, to a final concentration of 1%. After 10 min incubation at room temperature, fixation
was quenched by adding 125 mM ice-cold glycine, and flasks were washed three times with
ice-cold phosphate buffered saline (PBS). Cells were then scraped and washed three more
times with PBS, each washing step being followed by sedimentation at 1,300 x g. Pellets were
resuspended in 1mL lysis buffer (5 mM PIPES-pH = 8.0, 85 mM KCl, 0,5% NP-40, cOmplete
Mini cocktail tablets (Roche) and incubated at 4˚C for 15 mins with vortexing. Lysed cells
were sedimented at 13,000 x g, resuspended in 500 μL of sonication buffer (1% SDS, 10 mM
EDTA, 50 mM Tris-HCl-pH = 8.0, cOmplete Mini cocktail tablets) and sonicated on ice with
an MSE sonicator (6 pulses of 15s each at 15% amplitude with 30s off between each pulse). The
generated fragments were approximately 500 bp long, as determined experimentally. After
sedimentation at 13,000 x g, the supernatant was transferred into a new tube, diluted ten times
with IP buffer (0,01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH = 8.0),
167 mM NaCl) and supplemented with cOmplete Mini cocktail tablets. For each 500 μL ex-
tract, a mixture of 60 μL of Dynabeads protein A and 60 μL of Dynabeads protein G (Thermo-
Fisher), conjugated with 2 μg anti-HNF4α mouse monoclonal antibody (Abcam ab41898) or
anti-H3K27ac rabbit polyclonal antibody (Abcam ab4729) was added. After incubation at 4˚C
overnight, the beads were subsequently washed with buffer A (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM Tris-HCl (pH = 8.0), 0.15 M NaCl), buffer B (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris-HCl (pH = 8.0), 0.5 M NaCl) and buffer C (0,25 M LiCl, 1% NP40,
1% Na-deoxycholate, 1 mM EDTA, Tris-HCl (pH = 8.0), at 4˚C with permanent rotation for 5
mins. Following two washes with TE buffer (10 mM Tris-HCl, 10 mM EDTA, pH = 8.0), sam-
ples were eluted in 200 μL freshly prepared NaHCO3 (0,1 mM) supplemented with 1% SDS.
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Cross-links were reversed by overnight incubation at 65˚C. Samples were incubated with
20μg/mL RNAse at 37˚C for 1 hour, then proteinase K was added to 20 μg/mL and the mixture
was incubated for 2 hours at 45˚C. DNA was purified using High pure PCR template prepara-
tion kit (Roche). ChIP-seq libraries were prepared from 5 ng DNA with Ovation Ultralow
Library Systems (Nugen) according to manufacturer’s instructions. Libraries were sequenced
on Illumina HiScanSQ sequencer.
ChIP-seq data processing
Raw sequence files of the ChIP-seq samples were processed using a computational pipeline
[51] with the hg19 reference genome. ChIP-seq peaks were predicted using HOMER [52].
Artifacts, based on the blacklisted genomic regions of the Encyclopedia of DNA Elements [53],
were removed from the peak sets using BEDTools [54]. RPKM (Reads Per Kilobase per Million
mapped reads) values for the HNF4α sample were calculated on the summit -/+50 bp region
of the peaks; for the H3K27ac sample were calculated on the whole region of the histone signal.
Motif enrichment analysis was carried out by findMotifsGenome.pl. Pathway analysis was done
by annotatePeaks.pl using the KEGG database [55]. The average read density was determined
by annotatePeaks.pl [52]. Read distribution and average density heat maps were displayed by
Java TreeView [56]. Histogram and box plot were performed using GraphPad Prism version
6.00 for Windows (GraphPad Software, La Jolla California USA).
Quantitative PCR
A fraction of the DNA was used as a template for quantitative PCRs. The primers used were
designed with BiSearch [57] and their sequences are shown in Table 3. PCR products were
between 100 and 200 bp. qPCRs were performed in a total volume of 20 μL containing 1x
SYBR green mix (Roche), a 1/10 fraction of ChIP-enriched DNA, and 250 nM primers in a
96-well plate. Using sonicated genomic DNA samples at different dilutions, we generated stan-
dard curves, and relative amounts of immunoprecipitated DNA were calculated by extrapolat-
ing from the dilution curves. All standards and samples were run in duplicate. Plates were read
Table 3. List of qPCR primers.
Primer name Primer sequence
ABCC6 promoter F AGCCCATTGCATAATCTTCTAAGT
ABCC6 promoter R ATGGAGACCGCGTCACAG
ABCC6 exon31 F AAGTACACACAGCATGGCAG
ABCC6 exon31 R AGGACCTAGCAATACACAGG
β-globin F AGGACAGGTACGGCTGTCATC
β-globin R TTTATGCCCAGCCCTGGCTC
APOA1 F ATTGCAGCCAGGTGAGGAGAA
APOA1 R TTAGAGACTGCGAGAAGGAG
BLVRA F TTGTTTTGGAATGGGGGTGG
BLVRA R AAAAGGGAAGGCTGTGGCAA
BLVRB F CACCCTTTACCCTCTTTACC
BLVRB R GCCTGTGCTTTTGTGTTTAC
HPD F GATAGGGAAAACAGCCACCA
HPD R TTGGATGATGAGGACACAGG
PKLR F GTGGCTTACATGCTGTGGCT
PKLR R TAGGTGGGTTTTGGAGAGGA
doi:10.1371/journal.pone.0172020.t003
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with a LightCycler 480 real-time PCR machine (Roche). Enrichment of a particular DNA frag-
ment was calculated by comparing its relative concentration to control regions where no bind-
ing to the protein of interest is expected.
Accession number
Sequencing data were submitted to NCBI’s Sequence Read Archive (SRA) database under
accession number SRP096703 at the following URL:
https://www.ncbi.nlm.nih.gov/sra/?term=SRP096703
Supporting information
S1 Fig. Recruitment of HNF4α and H3K27ac at promoters. Histogram shows the average
tag density of HNF4α and H3K27ac peaks at those 451 HNF4α binding sites which overlap
with the transcription start site (TSS).
(TIF)
S2 Fig. ChIP-qPCR results showing HNF4α occupancy on seven genomic regions of
hepatic HNF4α target genes. Immunoprecipitation of chromatin from HepG2 cells was per-
formed with anti- HNF4α or IgG antibody untreated or treated with EGF for 30 mins or 24
hours. Enrichment was compared to negative control region (Beta globin) for TF occupancy
(y axis). HNF4α binding (black columns) is decreased after short EGF treatment (dark grey),
which is further diminished after long EGF treatment (light grey). BLVR A: Biliverdin A,
BLVR B: Biliverdin B, HPD: 4-hydroxyphenylpyruvate dioxygenase, PKLR: Pyruvate kinase,
liver and RBC, ABCC6: ATP-binding cassette subfamily C, member 6 and APOA1: Apolipo-
protein A1. S.D. is indicated on the figure.
(TIFF)
S1 Table. HNF4α target genes identified in ChIP-seq experiment on vehicle treated HepG2
cells.
(XLSX)
S2 Table. P values of one-sample t-test on individual HNF4α target genes investigated by
ChIP-qPCR.
(XLSX)
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